RWE in pharma: 5 minutes with…Michael Zaiac

In this ‘RWE in pharma’ interview series, we are putting various pharma experts in the spotlight and asking them to share their insight on how their industry has traditionally employed real-world evidence (RWE), how they envision this changing over the next few years and what their predictions of the impacts of the highly anticipated US FDA RWE Framework may be. This instalment features Michael Zaiac, Head of Medical Affairs in the Oncology Region Europe, at Novartis (Basel, Switzerland). Please could you introduce yourself, your organization(s) and tell us more about your role?  My name is Michael Zaiac. I trained in...